89bio's main value driver is Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. Management mentioned we should get its SHTG topline data by 2H2025. This could be a ...

In this article, I noted the prospects that this company is achieving regarding the development of its pipeline drug known as pegozafermin for the treatment of patients with metabolic-associated ...

The company is conducting trials with its experimental drug pegozafermin in patients with severe scarring of the liver. In patients who were not taking GLP-1s, 45% of those who were on Akero's ...

Additionally, the ongoing Phase 3 ENLIGHTEN program in NASH, which investigates pegozafermin in both non-cirrhotic and cirrhotic conditions, has garnered significant interest from key opinion ...

89bio intends to use the net proceeds from this proposed offering to fund ongoing clinical activities and development of pegozafermin, manufacturing related costs and other general corporate ...

The company's lead candidate, pegozafermin, is currently in Phase III clinical trials for the treatment of Metabolic Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). According ...